Publication:
Endothelial Dysfunction and Advanced Glycation End Products in Patients with Newly Diagnosed Versus Established Diabetes: From the CORDIOPREV Study.

Simple item page
dc.contributor.authorde la Cruz-Ares, Silvia
dc.contributor.authorCardelo, Magdalena P
dc.contributor.authorGutiérrez-Mariscal, Francisco M
dc.contributor.authorTorres-Peña, José D
dc.contributor.authorGarcía-Rios, Antonio
dc.contributor.authorKatsiki, Niki
dc.contributor.authorMalagón, María M
dc.contributor.authorLópez-Miranda, José
dc.contributor.authorPérez-Martínez, Pablo
dc.contributor.authorYubero-Serrano, Elena M
dc.date.accessioned2023-02-08T14:39:43Z
dc.date.available2023-02-08T14:39:43Z
dc.date.issued2020-01-16
dc.description.abstractEndothelial dysfunction and intima-media thickness of common carotid arteries (IMT-CC) are considered subclinical markers of atherosclerotic cardiovascular disease (ASCVD). Advanced glycation end products (AGEs) are increased in type 2 diabetes mellitus (T2DM) patients, compared with non-diabetics, being implicated in micro- and macrovascular complications. Our aim was to compare serum AGEs levels and subclinical atherosclerotic markers between patients with established and newly diagnosed T2DM. Among 540 patients with T2DM and coronary heart disease from the CORDIOPREV study, 350 patients had established T2DM and 190 patients had newly diagnosed T2DM. Serum levels of AGEs (methylglyoxal (MG) and N-carboxymethyl lysine (CML)) and subclinical atherosclerotic markers (brachial flow-mediated vasodilation (FMD) and IMT-CC) were measured. AGEs levels (all p
dc.identifier.doi10.3390/nu12010238
dc.identifier.essn2072-6643
dc.identifier.pmcPMC7019746
dc.identifier.pmid31963378
dc.identifier.pubmedURLhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7019746/pdf
dc.identifier.unpaywallURLhttps://www.mdpi.com/2072-6643/12/1/238/pdf?version=1579747633
dc.identifier.urihttp://hdl.handle.net/10668/14979
dc.issue.number1
dc.journal.titleNutrients
dc.journal.titleabbreviationNutrients
dc.language.isoen
dc.organizationIMIBIC
dc.pubmedtypeComparative Study
dc.pubmedtypeJournal Article
dc.pubmedtypeRandomized Controlled Trial
dc.rightsAttribution 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectCORDIOPREV
dc.subjectN-carboxymethyl lysine
dc.subjectadvanced glycation end products
dc.subjectendothelial dysfunction
dc.subjectflow-mediated vasodilation
dc.subjectintima-media thickness of common carotid arteries
dc.subjectmethylglyoxal
dc.subjecttype 2 diabetes mellitus
dc.subject.meshBiomarkers
dc.subject.meshCarotid Artery Diseases
dc.subject.meshCoronary Disease
dc.subject.meshCross-Sectional Studies
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshDiet, Healthy
dc.subject.meshEndothelium, Vascular
dc.subject.meshFemale
dc.subject.meshGlycation End Products, Advanced
dc.subject.meshHumans
dc.subject.meshLysine
dc.subject.meshMale
dc.subject.meshMiddle Aged
dc.subject.meshOlive Oil
dc.subject.meshPyruvaldehyde
dc.subject.meshSingle-Blind Method
dc.subject.meshVasodilation
dc.titleEndothelial Dysfunction and Advanced Glycation End Products in Patients with Newly Diagnosed Versus Established Diabetes: From the CORDIOPREV Study.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12
dspace.entity.typePublication

Files

Original bundle

Now showing 1 - 1 of 1
Thumbnail Image
Name:
PMC7019746.pdf
Size:
1017.54 KB
Format:
Adobe Portable Document Format
Download

Collections

Instituto de Investigación Biosanitaria de Granada (ibsGRANADA)

© 2023 – Repositorio Institucional de Salud de Andalucía - Fundación Pública Andaluza Progreso y Salud - Consejería de Salud y Consumo de la Junta de Andalucía